Producer
New York Blood Center Enterprises (NYBC)
New York Blood Center Enterprises (New York NY; nonprofit; formed 2019 by merger of NYBC + New England region blood centers + Southeast region; ~$700M revenue) is one of the largest US blood bank organizations — supplying blood to 200+ hospitals in New York, New Jersey, New England, and Southeast states. NYBC operates the New York City metropolitan area blood supply — one of the most complex transfusion medicine markets in the world. NYBC's research division has done foundational work in blood storage duration and transfusion outcomes. NYBC holds the blood supply contracts for Memorial Sloan Kettering, NYU Langone, and most major NYC hospital systems. In 2024, NYBC faced controversy when its lease for a Harlem community blood center — historically serving Black blood donors critical for sickle cell disease patients — was ended; advocates argued this reduced access to race-matched donors for sickle cell community.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input New York Blood Center Enterprises (NYBC) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something New York Blood Center Enterprises (NYBC) makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Blood Collection & Hospital Supply
65%Apheresis & Specialty Collections
15%Research & Transfusion Medicine
12%Testing & Manufacturing Services
8%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Chokepoint2024
NYBC's blood supply and its sickle cell disease community management role intersect in a way that exposes a biological supply chain dependency rarely discussed in healthcare: sickle cell disease patients (overwhelmingly Black Americans) who require regular red blood cell transfusions benefit from blood that is antigen-matched beyond ABO/Rh type — specifically matching for Kell, Duffy, Kidd, and other alloantigen systems that are more commonly compatible between donors and recipients of similar ethnic heritage. Black blood donors are statistically more likely to provide antigenically compatible blood for Black sickle cell patients. NYBC's Harlem community blood center served as a primary site for donor engagement with Black communities in the NYC area — its 2024 lease termination reduced access to this donor population, creating a supply chain equity issue within hospital transfusion medicine. The blood bank supply chain is thus not ethnically neutral: the racial composition of donor populations affects the immunological safety of transfusions for sickle cell patients, making community blood center placement an issue of both supply chain logistics and racialized medicine.
The New York Times ↗Origin2023
New York Blood Center was founded in 1964 by Dr. Aaron Kellner in New York City — emerging from New York Hospital's blood banking program to serve the growing demand of NYC's expanding hospital system. The founding period coincided with the Vietnam War era's transfusion medicine advances and the recognition that large metropolitan areas needed centralized, professionally managed blood banking rather than hospital-specific blood banks. NYBC became internationally recognized for transfusion medicine research, including contributions to the HIV-tainted blood supply crisis investigation in the 1980s (NYBC was among the first blood centers to implement HIV screening in 1985). The 2019 merger expanding NYBC's geographic scope to New England and the Southeast reflects the same consolidation economics driving Vitalant's formation: scale in testing, logistics, and regulatory compliance favors larger blood banking organizations.
New York Blood Center Enterprises ↗